• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

NAMPT as a Dedifferentiation-Inducer Gene: NAD+ as Core Axis for Glioma Cancer Stem-Like Cells Maintenance
Conclusion and Perspectives Gliomas are the most prevalent primary brain cancer in adults and include a broad category of tumors including astrocytoma, oligodendroglioma, and GBM. Regardless of tumor aggressiveness, malignancy, and infiltration, these glia-derived tumors rarely exceed a median survival time of 12–14 months. Driven by the infiltrative nature of these tumors, the clinical approach is difficult and relapses often occur with fatal consequences. These unsuccessful attempts to control glioma's fate have fostered research looking for more effective therapies. (GSCs) are a small subset of CD133&#...
Source: Frontiers in Oncology - May 2, 2019 Category: Cancer & Oncology Source Type: research

Treatment of pediatric cerebral radiation necrosis: a systematic review
Abstract Cerebral radiation necrosis (CRN) is a toxicity of radiation therapy that can result in significant, potentially life-threatening neurologic deficits. Treatment for CRN has included surgical resection, corticosteroids, hyperbaric oxygen therapy (HBOT), and bevacizumab, but no consensus approach has been identified. We reviewed the available literature to evaluate efficacy of treatment approaches. Using methods specified in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines when possible, we conducted searches of Ovid MEDLINE, Embase and Pubmed to identify studies re...
Source: Journal of Neuro-Oncology - July 19, 2016 Category: Cancer & Oncology Source Type: research

Phase II trial of hypofractionated intensity-modulated radiation therapy combined with temozolomide and bevacizumab for patients with newly diagnosed glioblastoma
This study demonstrated 90 % 6-month PFS and OS comparable to historic data in patients receiving standard treatment. Bevacizumab did not prevent radiation necrosis associated with this hypofractionated radiation regimen and large PTV volumes may have contributed to high rates of presumed radiation necrosis.
Source: Journal of Neuro-Oncology - December 19, 2014 Category: Cancer & Oncology Source Type: research

In search of a treatment for radiation-induced optic neuropathy
Opinion statement Radiation-induced optic neuropathy (RON) is an iatrogenic complication that causes severe, irreversible vision loss in one or both eyes within the months to years following radiation therapy. Posterior RON is a rare but devastating toxicity of radiation applied to the visual pathways to treat paranasal sinus and skull base tumors. Anterior RON is an unavoidable consequence of proton beam irradiation or ophthalmic plaque treatment of orbital, choroidal, or retinal tumors. Various treatments aimed at stabilizing and ideally reversing vision loss have been investigated but only in small cases serie...
Source: Current Treatment Options in Neurology - November 8, 2014 Category: Neurology Source Type: research

Rt-08 * proton therapy (pt) large-volume re-irradiation for recurrent glioma: overall survival (os) and toxicity outcomes
CONCLUSION: Large-volume PT re-irradiation for recurrent glioma is safe and associated with promising OS outcomes, particularly in the setting of bevacizumab-refractory tumors.
Source: Neuro-Oncology - November 3, 2014 Category: Cancer & Oncology Authors: Desai, B., Rockne, R., Rademaker, A., Raizer, J., Paleologos, N., Merrell, R., Grimm, S., Azeem, S., Hartsell, W., Sweeney, P., Swanson, K., Gondi, V. Tags: RADIATION THERAPY (CLINICAL AND/OR LABORATORY RESEARCH) Source Type: research